Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Neuroendocrine Tumors × durvalumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 27 Lung Neoplasms 12 Colorectal Neoplasms 11 Ovarian Neoplasms 10 Breast Neoplasms 10 Small Cell Lung Carcinoma 8 Urinary Bladder Neoplasms 7 Recurrence 6 Prostatic Neoplasms 6 Neoplasms 6 Head and Neck Neoplasms 6 Triple Negative Breast Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 5 Pancreatic Neoplasms 5 Diabetes Mellitus, Insulin-Dependent, 12 5 Carcinoma, Hepatocellular 5 Carcinoma 5 Neoplasm Metastasis 4 Recurrent Squamous Cell Lung Carcinoma 3 Multiple Myeloma 3 Mouth Neoplasms 3 Mesothelioma 3 Lymphoma, Large B-Cell, Diffuse 3 Lymphoma, Follicular 3 Kidney Neoplasms 3 Esophageal Neoplasms 3 Cholangiocarcinoma 3 Carcinoma, Renal Cell 3 Uterine Cervical Neoplasms 2 Urothelial Cancer 2

Interventions

Everolimus 13 Octreotide 6 Magnetic Resonance Spectroscopy 5 lanreotide 4 Sunitinib 4 gallium Ga 68 dotatate 3 cabozantinib 3 arginyllysine 3 Specimen Handling 3 Nivolumab 3 Etoposide 3 Carboplatin 3 Bevacizumab 3 telotristat ethyl 2 surufatinib 2 pembrolizumab 2 pazopanib 2 pasireotide 2 lutetium Lu 177 dotatate 2 X-Rays 2 Temozolomide 2 Phantoms, Imaging 2 Oxaliplatin 2 Ipilimumab 2 Erlotinib Hydrochloride 2 Doxorubicin 2 Cisplatin 2 Capecitabine 2 3-Iodobenzylguanidine 2 177Lu-DOTA-JR11 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03095274 2025-01-09

DUNE

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed

126 enrolled 18 charts

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡